Up to 80% of infants with hemolytic disease due to maternal alloimmunization, treated with
IUT, require at least one top-up transfusion for late anemia during the first 3 months of
life. Erythropoietin deficiency is also considered as a possible contributing factor to late
anemia and therefore we will assess the role of EPO (darbepoetin alfa) in the treatment of
these infants.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research